DCGI Gives Nod to Cipla to Import Moderna’s Covid-19 Vaccine for Emergency Use Authorisation


Mumbai-headquartered pharma major Cipla has got a nod from The Drugs Controller General of India (DCGI) on Tuesday for importing Moderna’s Covid-19 vaccine. This has made it the fourth vaccine in the country to be granted permission for the Emergency Use Authorisation or EUA.

According to NITI Aayog’s member (Health) VK Paul, the government is working out on the finer modalities for importing of Moderna’s Covid-19 vaccine. He also informed that India is in talks with Pfizer and Johnson & Johnson for adding to the basket of vaccines available in India.

Presently, the country has made available three Covid vaccines: Covishield, Covaxin, and Sputnik. Dr Paul also informed that the Moderna Covid vaccine will be introduced as a ready-to-use injectable vaccine in India. The vaccine can be stored for a seven months period at a temperature prescribed and its normal storage post opening of the vial is 30 days.

The Moderna vaccine, according to the World Health Organisation (WHO), has shown to have about a 94.1% efficacy in preventing against the Covid-19 beginning 14 days post the maiden dose. Its effectiveness is not altered by the new variants of SARS-CoV-2, WHO has stated based on evidence collected until now.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video